

October 05-07, 2013

Cremona

Italy



Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

Palazzo Trecchi

Via S. Trecchi, 20 - Cremona (Italy)

Dipartimento di Oncologia
Dipartimento di Chirurgia
Unità di Patologia Mammaria
- Breast Unit
Istituti Ospitalieri di Cremona
Cremona - Italy



ASCO®

American Society of Clinical Oncology

Making a world of difference in cancer care

ASCO® is a registered trademark of the American Society of Clinical Oncology®.
Used with permission. This is not an ASCO sponsored event.

Goal

Primary or neoadjuvant chemotherapy is now adopted by an increasing number of clinicians as a part of the multidisciplinary approach of either operable or locally advanced breast cancers. Historically this treatment modality was undertaken with the aim of shrinking the tumours and allowing to increase the conservation of the breast. Today primary chemotherapy is viewed as a means of testing the activity of a therapeutic approach in determining the disease outcome, since it allows a perfect quantifiable evaluation of the chemosensitivity or chemoresistance of any treated case. With respect to adjuvant chemotherapy, results are available quickly, and valuable information can be gathered from proof-of-concept studies involving a relatively small number of patients.

Primary or neoadjuvant chemotherapy, therefore, is the best model to identify baseline features able to predict which patients may be most likely to benefit or not from cytotoxic treatment. In addition, through the collection of tumor specimens before and after treatment, it is possible to explore the interaction between cytotoxic treatment and tumor biology in vivo in order to understand mechanisms and possibly provide surrogate parameters of treatment efficacy.

The Symposium will be organized to allow researchers and clinicians to share up-to-date information on state of the art, controversies and perspectives on this fascinating treatment modality.

Topics

- Overview of the results of cytotoxic treatment and endocrine therapy
- Methods of assessing response (Clinical palpation, mammography, echography, MRI)
- Predictive factors of disease response
- Changes in biological parameters before and after treatment
- Changes in surgical approaches

Educational Objectives

At the conclusion of this educational activity, participants should be able to:

- Apply knowledge gained to prepare for medical oncology and related specialty (knowledge, competence);
- Utilize current standards of care for patients with primary and locally advanced breast cancer (knowledge, competence, performance), Identify the great advantages of primary systemic therapy from a research perspective and also the problems preventing the recommendation to adopt this treatment modality instead of adjuvant therapy in clinical practice;
- Define pathological complete response and discuss its clinical significance;
- Incorporate recent advances in management of oncologic patients (knowledge, competence, performance); and
- Define molecular determinants for treatment of breast cancer (knowledge, competence, performance)
- Define the concept of a surrogate parameter of treatment efficacy and discriminate it from a prognostic parameter.



Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

Target Audience

This program should be of interest to physicians, medical oncologists, Surgeons, Radiation therapists, physician assistants and nurses/research nurses, health visitors, scientists and pharmacologists.

Educational Methods

- Lectures
- Discussion (Question-and-Answer sessions)
- Syllabi (hard copy and CD-ROM)

Lectures will be published on a special edition of JNCI Monographs

Evaluation

A course evaluation form will provide participants:

- with the opportunity to review each session and speaker
- to identify future educational needs
- to comment on any perceived commercial bias in the presentations.

Accreditation/Credit Designation


The U.O.M Patologia Mammaria - Breast Cancer Center of Az. Istituti Ospitalieri di Cremona is accredited by the CME to provide continuing medical education for physicians medical oncologists, surgeons, radiation therapists, health visitors, nurses and pharmacologists.

CME Certificates and Attendance Verification Certificates.

Certificate awarding _____ Credits or certificates documenting attendance will be distributed to

participants when an individual departs the conference. To obtain a CME certificate, participants must submit a completed evaluation questionnaire and a CME Verification Form.

Define the concept of a surrogate parameter of treatment efficacy and discriminate it from a prognostic parameter.



Planning committee

- U.O.M. Patologia Mammaria Breast Cancer Center - Azienda Istituti Ospitalieri di Cremona, Italy

Alberto Bottini, MD PhD

Daniele Generali, MD DPhil

- Medical Oncology, University of Turin, Italy

Alfredo Berruti, MD PhD

Luigi Dogliotti, MD PhD

- Medical Oncology and Breast Unit - Azienda Speciali Civili di Brescia, Italy

Edda Simoncini, MD PhD



Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy

Agenda

Saturday, October 05, 2013

16:00-17:30

Early Registration

17:30-18:15

Lecture Magistralis

Presenter: **L. Dogliotti, W. Miller**

ASCO State of the Art: Neoadjuvant Treatment in BC: When to use it, How to use it, Which patients to be selected.

C.A. Hudis

18:30-20:00

Opening Ceremony

President of the Symposium **A. Bottini**

Honorary President **L. Dogliotti**

President AIOM **S. Cascinu**

Dean University of Brescia **S. Pecorelli**

Director of Dept. of Oncology University of Turin **G. Scagliotti**

Director of Surgery Department, Azienda Istituti Ospitalieri

Cremona **M. Martinotti**

Director of Oncology Department, Azienda Istituti Ospitalieri

Cremona **I. Cafaro**

Director of Institution Azienda Istituti Ospitalieri Cremona

S. Mariani

20:00

Get together buffet

Sunday, October 06, 2013

08:00-09:00

Registration

09:00-10:30

Imaging Techniques for evaluation of tumor response

Chairmen: **A. Makris, E. Simoncini**

09:00-09:20

MRI, Digital Mammography and Sonography: tumor characteristics and tumor biology in primary setting

A. Makris

09:20-09:40

Multiparametric and multimodality imaging to identify radiological biomarkers for treatment response

M.A. Jacobs

09:40-10:00

RECIST for response (clinical and imaging) in neoadjuvant clinical trials

L.J. Esserman

10:00-10:30

Discussion

10:30-11:00

Coffee break



Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy

11.00-12.30

Integrated Oncology Management Surgical and Radiotherapy Approach

Chairmen: **A. Bottini, S. Magrini**

11.00-11.20

Best surgical approach for diagnosis, biological evaluation and research

J.M. Dixon

11.20-11.40

Sentinel Node Before and After Neoadjuvant Therapy

E. Mamounas

11.40-12.00

Radiation: MammoSite, Classical, Irradiation, HDR Interstitial Brachytherapy

S. Darby

12.00-12.30

Discussion

12.30-13.30

Lunch

13.30-18.30

Educational Session - Joint Symposium ASCO

Chairmen: **P.F. Conte, S. De Placido, S.M. Giulini**

13.30-14.00

Surgical Decisions before and after treatment

T.A. Buchholz

14.00-14.30

Radiotherapy issues after neoadjuvant treatments

J.R. Harris

14.30-15.00

State of the Art in neoadjuvant chemo- and endocrine-therapy

D. Cameron

15.30-16.00

Which are the intermediate end-points for primary systematic therapy?

G.V. Minckwitz

15.30-16.00

Which benefits from neoadjuvant in clinical routine and research perspective?

D. Hayes

16.00-16.30

Neoadjuvant model for testing emerging targeted therapies in breast cancer

G. Tortora

16.30-17.00

Psychological aspects of neoadjuvant from adjuvant therapy in breast cancer

K. Hermelink

17.00-18.30

Interactive Guided Discussion Panel-Audience on the Neoadjuvant Breast Cancer Treatment: Question and Answer Session generating guidelines for the Consensus Neoadjuvant Statement

Provokers: **M. De Laurentiis, L. Gianni**

20.00

Gala Dinner in a Historical Palace



Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

Monday, October 07, 2013

09:00-10:40

From bench to bedside: the clinical feed-back from the "path lab"

Chairmen: **F. De Braud, G. Viale**

09:00-09:20

The perfect pathology report after neoadjuvant therapy

A. Sapino

09:20-09:40

Early surrogate parameters of treatment activity: where are we now?

M. Dowsett

09:40-10:00

Outlines about pCR in neoadjuvant setting

S.B. Fox

10:00-10:20

Biological changes induced by the treatment: influences on clinical approach

W.F. Symmans

10:20-10:40

Discussion

10:40-11:00

Coffee-Break

11:00-12:20

Symposium Supported by FIRM

Chairmen: **A. Berruti, R. Labianca**

11:00-11:20

Window of opportunity: new approach for studying drug-tumor interaction

A.L. Harris

11:20-11:40

After primary systemic treatment: what to do accordingly to breast cancer subtypes?

A. Gennari

11.40-12.00

RNA disruption as a measure of drug response in neoadjuvant therapy

K.P.H. Pritzker

12:00-12:20

Neo-adjuvant trial design: time for a new conception

P. Bruzzi

12.20-12.40

Discussion

12.40-13.50

Lunch

13:50-15:50

Medical and Molecular Oncology Management in Primary Setting

Chairmen: **M. Aglietta, K. Pantel**

13:50-14:10

Inflammatory Breast Cancer: approach and treatment in neoadjuvant setting

M. Cristofanilli



Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

14:10-14:30

The role of genomic signature in the management of neoadjuvant treatment

L. Pusztai

14:30-14:50

Primary Systemic Therapy in Breast Cancer: Novel Molecular Marker Concepts

D. Generali

14:50-15:10

Back to the future for high doses in breast cancer treatment?

P. Pedrazzoli

15:10-15:30

Circulating biomarkers for prediction of response

M.G. Daidone

15:30-15:50

Discussion

15:50-16:50

A Networking Session for Young Investigators: Selected 9 Presentations

Chairmen: **S. Di Cosimo, V. Guarneri**

16:50-18:20

Conclusion remarks

The EUSOMA Guidelines: methodology and quality assurance for the best multidisciplinary approach in a Breast Unit

R. Mansel

Conclusive highlights of the meeting

A. Bottini, L. Dogliotti

Speakers

M. Aglietta

Università di Torino,
IRCC Candiolo, IT

A. Berruti

Università di Torino, A.O.U.
San Luigi, Orbassano, IT

A. Bottini

A.O. Istituti Ospitalieri,
Cremona, IT

P. Bruzzi

IST, Genova, IT

T.A. Buchholz

University of Texas MD
Anderson Cancer Center,
Houston, USA

I. Cafaro

A.O. Istituti Ospitalieri,
DIPO, Cremona, IT

D. Cameron

University of Edinburgh, UK

S. Cascinu

Azienda Ospedaliero-Uni-
versitaria Ospedali Riuniti
Umberto I - Salesi - Lancisi,
Ancona, IT

P.F. Conte

Università di Modena e
Reggio Emilia, IT

M. Cristofanilli

Fox Chase Cancer Center,
Philadelphia, USA

M. Daidone

INT, Milano, IT

S. Darby

University of Oxford,
Oxford, UK

F. De Braud

Fondazione IRCCS Istituto
Nazionale Tumori, Milano, IT

M. De Laurentiis

Università degli Studi di
Napoli Federico II, Napoli, IT

S. De Placido

Università degli Studi di
Napoli Federico II, Napoli, IT

S. Di Cosimo

Vall D'Hebron Institute of
Oncology, Barcelona, ES

J.M. Dixon

University of Edinburgh, UK

L. Dogliotti

Università di Torino, A.O.U.
San Luigi, Orbassano, IT

M. Dowsett

The Royal Marsden NHS
Trust, London, UK

L.J. Esserman

University of California/San
Francisco, San Francisco,
USA

S.B. Fox

Peter MacCallum Cancer
Institute, Melbourne, AUS

D. Generali

A.O. Istituti Ospitalieri,
Cremona, IT

A. Gennari

Ospedali Galliera,
Genova, IT

L. Gianni

Ospedale San Raffaele,
Milano, IT

S.M. Giulini

Università degli Studi di
Brescia, Brescia, IT

V. Guarneri

Università di Modena e
Reggio Emilia, IT

Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

D.F. Hayes

University of Michigan
Comprehensive Cancer
Center, Ann Arbor, USA

A.L. Harris

WIMM University of
Oxford, UK

J.R. Harris

Dana-Farber Cancer
Institute, Boston, USA

K. Hermelink

LMU University of
Munich, Munich, DE

C.A. Hudis

Memorial Sloan-Kettering
Cancer Center,
New York, USA

M.A. Jacobs

The Johns Hopkins Uni-
versity School of Medi-
cine, Baltimore, USA

M. Kaufmann

J.W. Goethe University
Hospital Frankfurt, DE

S. Magrini

Spedali Civili di Brescia,
DIPO, Brescia, IT

A. Makris

Mount Vernon Cancer
Centre, Middlesex, UK

R. Mansel

University Hospital of
Wales, Cardiff, UK

E.P. Mamounas

Aultman Cancer Center,
Canton, USA

S. Mariani

A.O. Istituti Ospitalieri,
Cremona, IT

M. Martinotti

A.O. Istituti Ospitalieri,
Cremona, IT

W. R. Miller

University of Edinburgh, UK

R. Labianca

Ospedali Riuniti di
Bergamo, Bergamo IT

K. Pantel

University Medical Cen-
ter Hamburg-Eppendorf,
Hamburg, DE

S. Pecorelli

Università degli Studi di
Brescia, Brescia, IT

P. Pedrazzoli

Fondazione IRCCS Policli-
nico San Matteo, Pavia, IT

K.P.H. Pritzker

MD FRCPC, Mount Sinai
Hospital, University of
Toronto, Toronto, CAN

L. Pusztai

UT MD Anderson Cancer
Center, Houston, USA

A. Sapino

Università di Torino, IT

G. Scagliotti

Università di Torino, A.O.U.
San Luigi, Orbassano, IT

E. Simoncini

Azienda Spedali Civili di
Brescia, Brescia, IT

W.F. Symmans

UT MD Anderson Cancer
Center, Houston, USA

G.P. Tortora

Università degli Studi di
Verona, Verona, IT

G. Viale

IEO Istituto Europeo On-
cologico, Milano, IT

G. Von Minckwitz

German Breast Group,
Neu-Isenburg, DE

Faculty**A. Berruti**

Università di Torino, A.O.U.
San Luigi, Orbassano, IT

A. Bottini

A.O. Istituti Ospitalieri,
Cremona, IT

T.A. Buchholz

University of Texas MD
Anderson Cancer Center,
Houston, USA

D. Cameron

University of Edinburgh, UK

P.F. Conte

Università di Modena e
Reggio Emilia, IT

M. Cristofanilli

Fox Chase Cancer Center,
Philadelphia, USA

M. Daidone

INT, Milano, IT

F. De Braud

Fondazione IRCCS Istituto
Nazionale Tumori, Milano, IT

S. De Placido

Università degli Studi di
Napoli Federico II, Napoli, IT

L. Dogliotti

Università di Torino, A.O.U.
San Luigi, Orbassano, IT

M. Dowsett

The Royal Marsden NHS
Trust, London, UK

S.B. Fox

Peter MacCallum Cancer
Institute, Melbourne, AUS

D. Generali

A.O. Istituti Ospitalieri,
Cremona, IT

L. Gianni

Ospedale San Raffaele,
Milano, IT

D.F. Hayes

University of Michigan
Comprehensive Cancer
Center, Ann Arbor, USA

A.L. Harris

WIMM University of
Oxford, UK

J.R. Harris

Dana-Farber Cancer
Institute, Boston, USA

C.A. Hudis

Memorial Sloan-Kettering
Cancer Center,
New York, USA

P. Pedrazzoli

Fondazione IRCCS Policli-
nico San Matteo, Pavia, IT

L. Pusztai

UT MD Anderson Cancer
Center, Houston, USA

A. Sapino

Università di Torino, IT

E. Simoncini

Azienda Spedali Civili di
Brescia, Brescia, IT

W.F. Symmans

UT MD Anderson Cancer
Center, Houston, USA

G.P. Tortora

Università degli Studi di
Verona, Verona, IT

G. Viale

IEO Istituto Europeo On-
cologico, Milano, IT

G. Von Minckwitz

German Breast Group,
Neu-Isenburg, DE

Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy

Scientific Secretariat

Manuela Milani


U.O.M. Patologia Mammaria Breast Cancer Center - Azienda Istituti Ospitalieri di Cremona, Italy

Carla Strina

U.O.M. Patologia Mammaria Breast Cancer Center - Azienda Istituti Ospitalieri di Cremona, Italy

Mirella Torta

Università di Torino - Dipartimento di Oncologia, A.O.U. San Luigi, Orbassano, Italy



General informations

Organizing Institution

U.O.M. Patologia Mammaria-Breast Cancer Center; Azienda Istituti Ospitalieri di Cremona-Cremona, Italy

Symposium Location

Palazzo Cittanova / Palazzo Trecchi,
Corso Garibaldi 135 Cremona (Italy)

Organizing Secretariat

Over Srl

Via Pagliari 4, 26100 Cremona (Italy)

Phone 0039 0372 23310

Fax 0039 0372 569605

congressi@overgroup.eu

www.overgroup.eu

Official language

The official congress language is English

Onsite registration hours

Attendees may pick up their badge and materials onsite at the symposium registration desk.

Saturday, October 05th 14.00 - 18.30 hrs

Sunday, October 06th 08.00 - 18.30 hrs

Monday, October 07th 08.00 - 18.00 hrs

Each Participant who is regularly registered will receive a badge with a bar-code.

Symposium badge will be required for admittance to all events. Please wear your badge so that it can be easily seen at all times.

Lost badges should be reported to the Registration staff immediately.

Identification colours

-  Blue - Congress Participant
-  Orange - Speaker
-  Green - Organization
-  Yellow - Press Staff
-  Grey - Exhibitor
-  Fuchsia - Accompanying Person



Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy

Registration Information

- On-site registration opens at 4.00 pm on Saturday, October 05, 2013 at the Town Hall (Sala Quadri)

- The Oncology Session of the conference will begin at 9.00 am on Sunday, October 06 and adjourn at 6.00 pm on Monday, October 07.

- Advanced registration is encouraged as space and materials are limited.

The "all inclusive" conference registration fee includes the tuition, final program syllabus, lunches, breaks and accommodation. The "regular" conference registration fee includes all services above mentioned except accommodation.

The deadline for advance registration is Friday, June 30, 2013.

Way to register

The only way to register is online by the congress site. Web-site under construction, online starting from September 2012.

Attendees are required to indicate clearly IN and OUT dates.

Telephone registrations are not accepted.

The following forms of payment are accepted:

- Credit cards (Master Card, VISA, and American Express)

- Cash (on-site registration only)

When registering online a receipt/confirmation letter will be automatically emailed to the e-mail address you list on the registration form.

Registration Fee Schedule

A reduced registrations fee has been established for physician assistants, nurses, health visitors and students. All claiming this reduced fee are required to submit a letter of introduction from the chairperson of their department with their registration form.

	Until May 31 st	After May 31 st
ALL INCLUSIVE FEE	€ 800,00	€ 900,00
REGULAR FEE	€ 600,00	€ 700,00
NURSES PHYSICIAN ASSISTANTS AND HEALTH VISITORS	€ 100,00	€ 150,00
STUDENTS (VALID ID REQUIRED)	FREE	FREE

Online registrations close on Wednesday, July 31 2012. After this date participants can register on-site only.

Refund/Cancellation Policy

The registration fee is refundable, inasmuch as € 250,00 per person, if a written request is received on or before Wednesday, July 31, 2013. No refunds will be granted after that date.

For additional information, contact Symposium Administration:

Over srl - Via Pagliari, 4 - 26100 Cremona Italy
Phone +39-0372 23310

congressi@overgroup.eu

www.overgroup.eu

Cancellation Statement

The Organizing Secretariat reserves the right to cancel the Symposium because of unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to each registrant.



Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

Special Assistance

Contact the Symposium Administration:
Over srl - Via Pagliari, 4 - 26100 Cremona Italy
Phone +39-0372 23310
congressi@overgroup.eu
www.overgroup.eu
(Ms. Daria Odelli or Ms. Gloria Platti)

If you need any other kind of information please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity.

Fax or e-mail Symposium Administration. All responses will be forwarded to the Program Chairs for consideration.

Accommodations

When you make registrations be sure to mention your preference about accommodation. Availability permitting it will be reserved a room in the hotel chosen.

- Dellearti Design Hotel
Via Geremia Bonomelli, 8 - 26100 Cremona (CR)
tel. +39 0372 23 131 fax. +39 0372 21654
e-mail - info@dellearti.com
- Hotel Impero
Piazza della Pace, 21 - 26100 Cremona (CR)
tel. +39 0372 413013 fax +39 0372 457295
e-mail: info@hotelimpero.cr.it
- Hotel Continental
Piazza della Libertà, 26 - 26100 Cremona (CR)
tel. +39.0372 43 41 41 fax. +39.0372.454873
e-mail: reception.hc@hotelcontinentalcremona.it

Ground Transportation

(prices are subjects to change)

- Cremona is served by two airports, Milan Linate and Milan Malpensa
- Taxicabs are available at an estimated cost of €150 / €200 to or from both Airports.
- Shuttle offers: www.malpensashuttle.it/ from Airports to Milan Central Station
- Trains from Milan Central Station to Cremona: www.trenitalia.com

Key Dates

- Symposium dates
October 05-07, 2013
- Registration discounts
by June 30, 2013
- Closing online registration
July 31, 2013
- On-site registration
October 05, 2013
- Registration cancellation deadline
by July 31, 2013
- Non refundable registration cancellation
after July 31, 2013



Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy



Cremona

Its History

Cremona was a Roman colony founded in 218 B.C., north of the river Po. In the Republican period it gained military, civil and commercial importance thanks to its geographical position. The political and economic importance of the medieval Cremona brought about a new urban development, which culminated in the construction of the superb complex of monuments forming the Palazzo Comunale Square and its imposing walls (1169 - 1187).

In 1334 Cremona was conquered by Visconti and finally became a part of the dukedom of Milan from 1420 till the unity of Italy.

In 1441 to celebrate her wedding with Francesco Sforza, Bianca Maria Visconti brought the town as a dowry and fostered its cultural and artistic renewal. This artistic production, which had as protagonists Bonifacio and Benedetto Bembo in the second half of the fifteenth century, went on also during the sixteenth century when Cremona was under the Spanish rule.

Its Violins

Cremona has always been considered the city which gave birth to the greatest violin-makers of any time. The importance of these exceptional masters is confirmed nowadays, as in the past, since the greatest violinists play instruments made by Stradivari or Guarneri del Gesù. The violin appears in the first half of the XVI century and Andrea Amati is the first of the Cremonensis violin-makers who gains importance in the manufacture of the bow instruments. In XVII

century Nicolò Amati, Andrea's nephew, made himself known: he continued his great predecessor's way.

Nicolò Amati works in a period in which real instrumental trends started. From the second half of XVII century the most famous of the violin-makers, Antonio Stradivari, began to work in Cremona.

Rich in his predecessors' experience, he developed the art of making stringed instruments which could meet with the requirements of the music of his time. Stradivari, making his violins, used the most refined techniques. He lived till 1737 and made more than one thousand works. Among the great manufacturers of the Cremonensis Art, Giuseppe Guarneri del Gesù had an important place. He was younger than Stradivari, but lived only a few years after him. We know about one hundred fifty violins made by him. It would be useless to seek for the refinement of lines shown by Amati's Brothers or by Stradivari in their works.

He tried, however, to combine the power of sound with the capacity of penetration and at the same time with softness.

Supports

Support has been requested to:

AIOM

AIRO

ANISC

AZIENDA ISTITUTI OSPITALIERI DI CREMONA

CAMERA DI COMMERCIO DI CREMONA

COMUNE DI CREMONA

DIPO CREMONA

EORTC

ESMO

ORDINE DEI MEDICI DI CREMONA

PROVINCIA DI CREMONA

SIC

SICO

SIRM

SIS

UNIVERSITÀ DI BRESCIA

UNIVERSITÀ DI TORINO



Fifth International Symposium

**PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER**

Towards the rapid assessment of therapy efficacy

Sponsor



Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy

Fifth International Symposium

PRIMARY SYSTEMIC TREATMENT
IN THE MANAGEMENT OF
OPERABLE BREAST CANCER

Towards the rapid assessment of therapy efficacy

October 05-07, 2013

Cremona

Italy

Symposium Administration:



Over srl

Via Pagliari, 4

26100 Cremona Italy

Phone +39-0372 23310

congressi@overgroup.eu

www.overgroup.eu